Continue active refreshing of this index's data?
Continue active refreshing of this index's data?
News & Research
Most Recent News & Research

Thematic indices can offer diversification and market-beating returns, in some cases by using innovative index methodologies, says Christoph Schon at Qontigo.

Using Axioma’s Macroeconomic Projection Model, we decompose the risk factors that drove returns in the STOXX Global Broad Infrastructure between 2020 and 2022. The results show the index had a positive exposure to the risk model’s inflation factors, meaning it stood to benefit from rising global inflation expectations.

Analytics | Index | Benchmarks
Together in ’22: Qontigo Investment Intelligence Summit returns to London, New York
After two years of virtual gatherings, I’m thrilled to announce that the flagship Qontigo Investment Intelligence Summit will return in person this May. This year’s Summit, which we have called ‘Together in ’22,’ will take place in London on May 5 and in New York on May 19. The two events will offer insights on some of the most important […]

This whitepaper evaluates two thematic investment strategies – STOXX® Global Ageing Population (“Ageing Population”) and STOXX® Global Millennials (“Millennials”) – which seek exposure to these two distinct generations.

In this paper we analyzed four tech-oriented thematic indices’ performance and risk through a factor lens leveraging Axioma’s Worldwide Fundamental Factor Model, and also compared their characteristics to the broad market indices.

The COVID-19 crisis has accentuated long-term trends in the European equity market, with Health Care solidifying its dominance in the STOXX® Europe 600 Index, and Banks shedding further ground.

Analytics | ESG & Sustainability
Entis: Artificial and Human Intelligence Combine to Identify Sustainable Development Investments
As thematic investing is gaining momentum, investors are confronted with the question of how to identify companies that are relevant to a specific theme.

A custom index of stocks with exposure to virus therapy and prophylactics leads market gains amid the COVID-19 pandemic.